

References

1. Benatar M, Sanders DB, Burns TM, et al; Task Force on MG Study Design of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Recommendations for myasthenia gravis clinical trials. *Muscle Nerve*. 2012;45(6):909-917.
2. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. *J Clin Med*. 2021;10(11):2235.
3. Gupthill JT, Benatar M, Granit V, et al; MGNet Clinical Trial Outcome Measure Working Group. Addressing outcome measure variability in myasthenia gravis clinical trials. *Neurology*. 2023;101(10):442-451.
4. Nguyen-Cao TM, Gelinas D, Griffin R, Mondou E. Myasthenia gravis: historical achievements and the "golden age" of clinical trials. *J Neurol Sci*. 2019;406:116428.
5. Song Z, Zhang J, Meng J, et al. Different monoclonal antibodies in myasthenia gravis: a Bayesian network meta-analysis. *Front Pharmacol*. 2022;12:790834.